Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,371.41
(
-0.21%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 100683

Wednesday, 08/04/2010 2:36:22 PM

Wednesday, August 04, 2010 2:36:22 PM

Post# of 257268

Teleprevir had some anemia issues in the 8-week arm.

A key distinction is that, according to VRTX, EPO was not permitted in the protocols of the ADVANCE and PROVE-3 studies.

discontinuations due to AE's when compared to the control group appears to be worse for Telaprevir than for Boceprevir.

The exclusion of EPO, which made it more difficult to keep Telaprevir patients with anemia enrolled in the trials, renders the comparison of discontinuation rates problematic.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today